| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to the consolidated net loss for the three months ended March 31, 2025 and 2024 is included at the bottom of the table below.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
Revenues |
|
$ |
14,063 |
|
|
$ |
7,902 |
|
Cost of revenues |
|
|
655 |
|
|
|
1,269 |
|
Program expenses (1) |
|
|
|
|
|
|
zuranolone (ZURZUVAE) |
|
|
12,010 |
|
|
|
5,257 |
|
SAGE-319 |
|
|
1,667 |
|
|
|
953 |
|
SAGE-324 |
|
|
(837 |
) |
|
|
3,831 |
|
dalzanemdor |
|
|
(30 |
) |
|
|
23,668 |
|
Other research and development programs |
|
|
3,505 |
|
|
|
9,456 |
|
Non-program expenses (2) |
|
|
19,258 |
|
|
|
22,131 |
|
People and staff augmentation |
|
|
37,851 |
|
|
|
45,910 |
|
Restructuring |
|
|
513 |
|
|
|
(597 |
) |
Other segment items (3) |
|
|
1,685 |
|
|
|
4,507 |
|
Net loss |
|
$ |
(62,214 |
) |
|
$ |
(108,483 |
) |
|
|
|
|
|
|
|
(1) Includes external research and development, and selling, general and administrative expenses. |
|
(2) Includes information technology, infrastructure, facilities, legal, commercial data and systems, chemistry platform, |
|
intellectual property, and other general and administrative expense. |
|
(3) Includes stock-based compensation expense, interest income, and other (income) expense. |
|
|